Valuation dashboard for Solid Biosciences Inc. (SLDB) with P/E N/A, P/B 3.35, EV/EBITDA -4.09 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $8.72, SLDB has negative trailing earnings (P/E not meaningful) and an ROE of -72.28%. Market capitalisation stands at $858M.
Balance sheet quality for SLDB: current ratio of 6.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.35 |
| EV / EBITDA | -4.09 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.41 |
| vs Current Price | -95.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SLDB | Solid Biosciences Inc. | $858M | 3.35 | -72.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $8.72 |
| Market Cap | $858M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -72.28% |
| Return on Invested Capital | -53.81% |
| Return on Assets | -49.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANNX · AURA · AUTL · BNTC · DSGN · LBRX · NMRA
Explore sector: Healthcare · Biotechnology
More sections of SLDB: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks